• Regenxbio priced a public offering that includes 1,111,111 pre-funded warrants at USD 9 per warrant.
• Warrants were priced at USD 9.00 per warrant, before underwriting discounts and commissions.
• Gross proceeds expected at about USD 100 million, before fees and expenses; closing targeted for July 20, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607170700PR_NEWS_USPR_____PH06838) on July 17, 2026, and is solely responsible for the information contained therein.